Related Experiment Videos
Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies
Abstract:
PMM is a water-soluble alternative to HMM. PMM has been administered as an intravenous infusion to 17 patients in a Phase I clinical trial. The dose-limiting toxicities were nausea and vomiting which were observed in all patients at 500 mg m-2 and above. The dose was not escalated above 1300 mg m-2 where nausea and vomiting were severe, prolonged (greater than 24 h) and poorly controlled by anti-emetics. Haematological, hepatic and renal toxicities were not observed. Neurological toxicity was not observed at low doses (less than 500 mg/m2) but could not be determined at higher doses due to intensive anti-emetic therapy. Pharmacokinetic studies (100-500 mg m-2) indicated that PMM plasma levels are dose-dependent and that the PMM disposition-phase half-life is prolonged in patients with abnormal liver function. It is concluded that the severe toxicity of PMM will limit the clinical utility of this compound and hence Phase II trials are not recommended.
Insights
Phase I trials of PMM (a water-soluble alternative to HMM) revealed severe dose-limiting toxicities, primarily nausea and vomiting. These toxicities limit PMM
Area of Science:
- Pharmacology
- Clinical Toxicology
Background:
- PMM (a water-soluble alternative to HMM) was evaluated for clinical utility.
- Intravenous administration was used in a Phase I clinical trial.
Purpose of the Study:
- To assess the safety and tolerability of PMM in patients.
- To determine dose-limiting toxicities and pharmacokinetic properties of PMM.
Main Methods:
- A Phase I clinical trial involving 17 patients.
- Intravenous infusion of PMM at escalating doses.
- Monitoring for adverse events, including haematological, hepatic, renal, and neurological toxicities.
- Pharmacokinetic studies to evaluate plasma levels and half-life.
Main Results:
- Dose-limiting toxicities of nausea and vomiting occurred in all patients at 500 mg m-2 and above.
- Severe, prolonged nausea and vomiting occurred at doses >1300 mg m-2, uncontrolled by anti-emetics.
- No haematological, hepatic, or renal toxicities were observed.
- Neurological toxicity was not observed at low doses (<500 mg/m2).
- PMM plasma levels were dose-dependent.
- PMM half-life was prolonged in patients with abnormal liver function.
Conclusions:
- Severe toxicity, particularly nausea and vomiting, is a significant limitation for PMM's clinical utility.
- Phase II trials are not recommended due to the observed toxicity profile.
- Further investigation into PMM's safety and efficacy is warranted, especially concerning liver function impacts.